hnRNP-E1 Polypeptide Mutations for Homocysteine-Independent mRNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to control the binding of hnRNP-E1 to poly(rC)/poly(U)-rich mRNAs independently of homocysteine levels, which is crucial for modulating protein expression in health conditions such as folate deficiency.
Innovation Solution
Engineered hnRNP-E1 polypeptides with specific point mutations at positions like C293, C54, C158, and C201 confer homocysteine-independent binding to poly(rC)/poly(U)-rich cis elements, allowing for the modulation of mRNA translation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If wild-type hnRNP-E1 is used, then binding to poly(rC)/poly(U)-rich mRNAs occurs through homocysteinylation, but binding control is dependent on homocysteine levels which limits therapeutic flexibility
Solution Approach 1:
The patent applies parameter changes by mutating specific cysteine residues (positions 54, 158, 201, 293) to serine or alanine in the hnRNP-E1 protein. This amino acid substitution changes the chemical parameters of the protein, eliminating the need for homocysteine-mediated S-sulfenylation while preserving RNA binding capability. The mutant proteins bind poly(rC)/poly(U)-rich mRNAs independently of homocysteine concentration, providing therapeutic flexibility.
2Reliability
If homocysteinylation is required for binding, then specific mRNA targets are recognized, but the mechanism requires cellular folate deficiency conditions which limits applicability
Solution Approach 1:
The patent extracts the essential binding function from the homocysteinylation process by creating mutant hnRNP-E1 proteins that retain RNA recognition capability without requiring the homocysteine modification step. The cysteine-to-serine/alanine mutations remove the thiol group necessary for homocysteine attachment while preserving the overall protein structure and RNA-binding interface, thereby decoupling specificity from physiological condition dependency.
Solution Approach 2:
Instead of requiring homocysteine addition to enable binding (wild-type mechanism), the patent inverts the approach by creating mutants that bind constitutively without homocysteine. The mutation strategy reverses the logical sequence: rather than 'no binding without homocysteine,' the mutants achieve 'binding without requiring homocysteine,' providing constant activity regardless of cellular folate status.
3Ease of operation
If hnRNP-E1 binding is controlled by homocysteine levels, then natural regulation occurs, but therapeutic intervention capability is reduced
Solution Approach 1:
The mutant hnRNP-E1 proteins exhibit self-service characteristics by autonomously binding to target mRNAs without requiring external homocysteine supply or cellular metabolic conditions. The constitutive binding activity eliminates dependence on cellular folate metabolism pathways, allowing the therapeutic agent to function independently of host physiological variability and provide reliable, predictable activity.
Data Source
AI summary
Described herein are compositions relating to engineered hnRNP-E1 variant polypeptides, nucleic acids encoding such polypeptides, engineered hnRNP-E1 compositions, and methods of use thereof. In some embodiments, the engineered hnRNP-E1 polypeptide contains a C293S substitution and retains the ability to bind to a poly(rC)- and poly(U)-rich 5′-UTR element in its cognate mRNA targets in the absence of homocysteine. In some cases, the engineered hnRNP-E1 compositions provided herein are useful to increase the translation of a subset of mRNAs or to treat certain health conditions as described herein.